Journal
BLOOD REVIEWS
Volume 51, Issue -, Pages -Publisher
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2021.100888
Keywords
Hairy cell leukemia; Treatment; Cladribine; Rituximab; Vemurafenib; Dabrafenib; Trametinib; Moxetumomab pasudotox; Minimal residual disease
Categories
Funding
- Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research
Ask authors/readers for more resources
Hairy cell leukemia is a B-cell malignancy driven by the BRAF V600E mutation. Combination therapy with purine analogs and rituximab can achieve higher rates of minimal residual disease eradication. BRAF inhibitors, Ibrutinib, and moxetumomab pasudotox have shown efficacy in inducing remission but may require chronic use to prevent relapse.
Hairy cell leukemia (HCL) is an indolent B-cell malignancy, usually driven by the BRAF V600E mutation. For 30 years, untreated and relapsed HCL was successfully treated with purine analogs, but minimal residual disease (MRD) remained in most patients, eventually causing relapse. Repeated purine analogs achieve decreasing efficacy and increasing toxicity, particularly to normal T-cells. MRD-free complete remissions (CRs) are more common using rituximab with purine analogs in both 1st-line and relapsed settings. BRAF inhibitors and Ibrutinib can achieve remission, but due to persistence of MRD, must be used chronically to prevent relapse. BRAF inhibition combined with Rituximab can achieve high MRD-free CR rates. Anti-CD22 recombinant immunotoxin moxetumomab pasudotox is FDA-approved in the relapsed setting and is unique in achieving high MRD-free CR rates as a single-agent. Avoiding chemotherapy and rituximab may be important in ensuring both recovery from COVID-19 and successful COVID-19 vaccination, an area of continued investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available